Clinical Trial Update: Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating everolimus with investigator's choice chemotherapy in advanced triple-negative breast cancer with luminal androgen receptor subtype is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Fudan University | Conditions: Triple Negative Breast Cancer, Metastatic Breast Cancer | Phase 3 | Status: RECRUITING